The stock price of TherapeuticsMD, Inc (TXMD) kept oscillating between $0.31 and $0.29, during the last traded session. The stock price in pre-market, during the last check, was up 8.77% at $0.31. The rise came right after the filing with the SEC on February 1, 2022.
TherapeuticsMD, Inc (TXMD) has a 12 month low of $0.26 and a 12 month high of $2.75. The firm has a market capitalization of $131.38 million, and a beta of 1.75.
TherapeuticsMD, Inc is a pharmaceutical company, founded in 1907 and headquartered in Boca Raton, Florida, United States of America. The company’s innovation, SYMBODA, creates progressed hormonal treatment drug items to empower the conveyance of bio-identical hormones through an assortment of dose structures and administration routes.
Financials
The company released its financial results for Q3 of FY21 on November 11, 2021.
- The total revenue reported was $$25.4 million.
- The EPS reported was -$0.11 against the estimated earnings of -$0.10.
- The total gross profit was reported to be $20.12 million.
- The net earnings reported was to be -$47.2 million.
According to Zacks Investment Research, the consensus EPS forecast for the fourth quarter of FY21 is $-0.06.
TherapeuticsMD News
TherapeuticsMD, Inc. (TXMD) was targeted for a huge development in short interest during the period of January. As of January 15, 2021, there was short interest totaling 25.35 million shares, posting a growth of 35.2% from December 31st a total of 18.75 million shares.
Apart from that, Director Cooper C. Collins procured 1 million shares of TherapeuticsMD stock in an exchange that happened on Thursday, November 18, 2021. The shares were gained at a cost of $0.58 per share, for a complete exchange of $580,000. This was reported in a filing with the SEC.
What do the analysts say about TXMD?
There is a consensus among analysts covering TherapeuticsMD that breakeven is near. By 2023, they expect the company to turn a profit of US$23m following a final loss in 2022.
